Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Familial alzheimer’s disease lymphocytes respond differently than sporadic cells to oxidative stress: upregulated p53-p21 signaling linked with presenilin 1 mutants

  • Wojsiat, Joanna
  • Laskowska-Kaszub, Katarzyna
  • Alquézar, Carolina
  • Bialopiotrowicz, Emilia
  • Esteras, Noemí
  • Zdioruk, Mykola
  • Martín-Requero, Ángeles
  • Wojda, Urszula
16 p.-7 fig.-2 tab., Familial (FAD) and sporadic (SAD) Alzheimer's disease do not share all pathomechanisms, but knowledge on their molecular differences is limited. We previously reported that cell cycle control distinguishes lymphocytes from SAD and FAD patients. Significant differences were found in p21 levels of SAD compared to FAD lymphocytes. Since p21 can also regulate apoptosis, the aim of this study was to compare the response of FAD and SAD lymphocytes to oxidative stress like 2-deoxy-D-ribose (2dRib) treatment and to investigate the role of p21 levels in this response. We report that FAD cells bearing seven different PS1 mutations are more resistant to 2dRib-induced cell death than control or SAD cells: FAD cells showed a lower apoptosis rate and a lower depolarization of the mitochondrial membrane. Despite that basal p21 cellular content was lower in FAD than in SAD cells, in response to 2dRib, p21 mRNA and protein levels significantly increased in FAD cells. Moreover, we found a higher cytosolic accumulation of p21 in FAD cells. The transcriptional activation of p21 was shown to be dependent on p53, as it can be blocked by PFT-α, and correlated with the increased phosphorylation of p53 at Serine 15. Our results suggest that in FAD lymphocytes, the p53-mediated increase in p21 transcription, together with a shift in the nucleocytoplasmic localization of p21, confers a survival advantage against 2dRib-induced apoptosis. This compensatory mechanism is absent in SAD cells. Thus, therapeutic and diagnostic designs should take into account possible differential apoptotic responses in SAD versus FAD cells., This research was supported by the Joint Programming for Neurodegenerative Diseases (JPND) grant 2/BIOMARKAPD/JPND/2012 and the Polish National Science Centre grant NN401 596840 to UW, and by the Spanish Ministry of Economy and Competitiveness (CTQ-2015-66313-R) to AM-R, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases

  • Connolly, Niamh M. C.
  • Theurey, Pierre
  • Adam-Vizi, Vera
  • Bazan, Nicolas G.
  • Bernardi, Paolo
  • Bolaños, Juan P.
  • Culmsee, Carsten
  • Dawson, Valina L.
  • Deshmukh, Mohanish
  • Duchen, Michael R.
  • Düssmann, Heiko
  • Fiskum, Gary
  • Galindo, María F.
  • Hardingham, Giles E.
  • Hardwick, J. Marie
  • Jekabsons, Mika B.
  • Jonas, Elizabeth A.
  • Jordán, Joaquín
  • Lipton, Stuart A.
  • Manfredi, Giovanni
  • Mattson, Mark P.
  • McLaughlin, BethAnn
  • Methner, Axel
  • Murphy, Anne N.
  • Murphy, Michael P.
  • Nicholls, David G.
  • Polster, Brian M.
  • Pozzan, Tulio
  • Rizzuto, Rosario
  • Satrústegui, Jorgina
  • Slack, Ruth S.
  • Swanson, Raymond A.
  • Swerdlow, Russell H.
  • Will, Yvonne
  • Ying, Zheng
  • Joselin, Alvin
  • Gioran, Anna
  • Moreira Pinho, Catarina
  • Watters, Orla
  • Salvucci, Manuela
  • Llorente-Folch, Irene
  • Park, David S.
  • Bano, Daniele
  • Ankarcrona, Maria
  • Pizzo, Paola
  • Prehn, Jochen H. M.
Neurodegenerative diseases are a spectrum of chronic, debilitating disorders characterised by the progressive degeneration and death of neurons. Mitochondrial dysfunction has been implicated in most neurodegenerative diseases, but in many instances it is unclear whether such dysfunction is a cause or an effect of the underlying pathology, and whether it represents a viable therapeutic target. It is therefore imperative to utilise and optimise cellular models and experimental techniques appropriate to determine the contribution of mitochondrial dysfunction to neurodegenerative disease phenotypes. In this consensus article, we collate details on and discuss pitfalls of existing experimental approaches to assess mitochondrial function in in vitro cellular models of neurodegenerative diseases, including specific protocols for the measurement of oxygen consumption rate in primary neuron cultures, and single-neuron, time-lapse fluorescence imaging of the mitochondrial membrane potential and mitochondrial NAD(P)H. As part of the Cellular Bioenergetics of Neurodegenerative Diseases (CeBioND) consortium (www.cebiond.org), we are performing cross-disease analyses to identify common and distinct molecular mechanisms involved in mitochondrial bioenergetic dysfunction in cellular models of Alzheimer’s, Parkinson’s, and Huntington’s diseases. Here we provide detailed guidelines and protocols as standardised across the five collaborating laboratories of the CeBioND consortium, with additional contributions from other experts in the field., We acknowledge the support of the CeBioND EU Joint Programme for Neurodegenerative Disease Research (JPND; www.jpnd.eu). The programme is supported through the following national funding organisations: Canada, CIHR; Germany, BMBF; Ireland: Science Foundation Ireland (14/JPND/ B3077); Italy: MIUR; Sweden: VR., Peer reviewed